Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population (original) (raw)

Arthritis Care & Research, 2016

Patient-Reported Outcomes in RA Patients Treated With Tofacitinib or bDMARDs in Real-life Conditions in Two Latin American Countries

Renato Guzman

2021

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

Arthritis Care & Research, 2017

The 6-month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib

Burak Öz

Annals of Medical Research, 2021

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

Alan Worsley, Ying He

BMC Musculoskeletal Disorders, 2013

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

Mark Genovese

Annals of Internal Medicine, 2013

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Arthritis Research & Therapy, 2015

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

Shahin Jamal

ACR Open Rheumatology, 2019

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Cristiano Moura

Arthritis research & therapy, 2018

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study

Shrikant Wagh

Arthritis & Rheumatology, 2019

Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

New England Journal of Medicine, 2012

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

International Journal of Rheumatic Diseases, 2016

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

Alejandro alvarez

Annals of the Rheumatic Diseases, 2011

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

Francisco Blanco

Annals of the Rheumatic Diseases, 2012

Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

Geoffrey Littlejohn

Clinical Rheumatology, 2021

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib

Maria Kózka

Therapeutics and Clinical Risk Management, 2017

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Erika García, Karina Santana, Daniel Xavier Xibille Friedmann

Reumatología Clínica, 2017

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study

Yoshiya Tanaka

Rheumatology (Oxford, England), 2017

Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain

María Montoro

Drug Discoveries & Therapeutics

Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Yoshiya Tanaka

Modern rheumatology / the Japan Rheumatism Association, 2015

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology (Oxford, England), 2016

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)

Alomgir Hossain

The Cochrane database of systematic reviews, 2016

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

Yoshiya Tanaka

Rheumatology, 2011

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis

Alomgir Hossain

The Cochrane database of systematic reviews, 2017

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

2019

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Jamie Geier

Annals of the rheumatic diseases, 2017

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

L. Rowell

Annals of the Rheumatic Diseases, 2014

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

Mark Genovese

Arthritis research & therapy, 2016

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

Rheumatology and Therapy, 2019

Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial

Arthritis care & research, 2015